Journal of Pediatric Neurology 2020; 18(04): 206-209
DOI: 10.1055/s-0040-1702238
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Aicardi–Goutières Syndrome Type 2: A Report on Two Cases with Different Phenotypes Caused by RNASEH2B Gene Mutations

Anna Portale
1   Department of Clinical and Experimental Medicine, Pediatrics Postgraduate Residency Program, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
,
Marina Mazzurco
1   Department of Clinical and Experimental Medicine, Pediatrics Postgraduate Residency Program, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
,
Laura Portale
1   Department of Clinical and Experimental Medicine, Pediatrics Postgraduate Residency Program, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
,
Piero Pavone
2   Department of Clinical and Experimental Medicine, Unit of Clinical Pediatrics, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
,
Enrico Bertini
3   Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative diseases, IRCCS Bambino Gesù Children's Hospital, Rome, Italy
,
Agata Polizzi
4   Department of Educational Sciences, University of Catania, Catania, Italy
,
Andrea D. Praticò
5   Department of Clinical and Experimental Medicine, Unit of Rare Diseases of the Nervous System in Childhood, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
,
Martino Ruggieri
5   Department of Clinical and Experimental Medicine, Unit of Rare Diseases of the Nervous System in Childhood, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
› Author Affiliations
Further Information

Publication History

12 August 2019

16 January 2020

Publication Date:
15 March 2020 (online)

Preview

Abstract

Aicardi–Goutières syndrome (AGS) is a rare disorder characterized by acquired microcephaly, cerebral calcifications, leukodystrophy, cerebral atrophy, chronic lymphocytosis, and increased interferon-α in cerebrospinal fluid. We report on two children affected by AGS type 2, caused by mutations in RNASEH2B. The first child had the mutation c.529G > A (p.A177T) and presented with an atypical and mild phenotype, with delayed psychomotor development, calcifications of the brain white matter and basal ganglia, and interferon signature positivity. The disease course was stable. The second child presented the mutation c.554T > G (p.V185G) and showed a later onset (15 months) and a more progressive clinical course with functional inability in the upper limbs, steppage gait, and irritability. Despite immunoglobulin therapy, she developed to progressive tetraparesis and severe hypotonia. This case report highlights that RNASEH2B mutation cannot fully predict the phenotype of AGS type 2 when a mutation c.529G > A occurs. Moreover, an earlier symptomatology may be not related to a more severe prognosis or to a partial or absent response to treatment.